ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
2,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
2,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
3,1,Lung operation,Bronchial and pulmonary therapeutic procedures,Respiratory tract therapeutic procedures,Surg,N
4,1,Monoplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
5,1,Abnormal loss of weight,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
5,2,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
5,3,Clostridium difficile infection,Clostridia infections,Bacterial infectious disorders,Infec,N
5,4,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
5,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
5,6,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
5,7,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
5,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,9,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
5,10,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
6,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,Y
6,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
6,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
6,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
7,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
7,2,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
8,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
9,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
9,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
9,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
9,4,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
9,5,Myalgia,Muscle pains,Muscle disorders,Musc,N
10,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
10,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
10,3,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
10,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
10,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
10,6,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
11,1,Headache,Headaches NEC,Headaches,Nerv,N
12,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
13,1,Glaucoma,Glaucomas (excl congenital),Glaucoma and ocular hypertension,Eye,N
14,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
14,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
14,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
14,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
15,1,Brain neoplasm,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,Y
16,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
17,1,Cellulitis orbital,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
17,2,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
18,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
18,2,Transplant failure,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
19,1,Ostectomy,Bone therapeutic procedures NEC,Bone and joint therapeutic procedures,Surg,N
20,1,Ageusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
20,2,Alopecia,Alopecias,Skin appendage conditions,Skin,N
20,3,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
20,4,Therapy partial responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
21,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
22,1,Skin neoplasm bleeding,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
23,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
24,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
25,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
26,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
27,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
28,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
29,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
30,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
30,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
31,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
32,1,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
33,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
34,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
34,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
35,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
35,2,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
36,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
37,1,Lung adenocarcinoma,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
38,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
38,2,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
38,3,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
38,4,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
38,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
38,6,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
39,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
39,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
39,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
40,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
40,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
40,3,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
40,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
40,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
41,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
42,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
42,2,Large intestine perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
43,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
43,2,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
44,1,Hypomagnesaemia,Magnesium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
44,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
44,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
45,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
46,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
47,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
48,1,Intestinal haemorrhage,Intestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
49,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
49,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
50,1,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
51,1,Bronchial carcinoma,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
52,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
53,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
53,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
54,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
54,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
54,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
54,4,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
54,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
54,6,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
55,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
55,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
55,3,Dysgeusia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
55,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
55,5,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
56,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
57,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
57,2,Cyst,Mass conditions NEC,Tissue disorders NEC,Genrl,N
57,3,Ill-defined disorder,General signs and symptoms NEC,General system disorders NEC,Genrl,N
57,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
57,5,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
58,1,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
59,1,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
59,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
60,1,Gastric perforation,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
61,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
62,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
63,1,Dermatitis,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
64,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
64,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
65,1,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
